Recombinant Human Anti-CD37 x Human Anti-CD64 Bispecific Antibody (scFv-CH1/CL) (BSCC-H293)

Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD37 antibody variable domain is fused to CH1 and the other scFv from an anti-CD64 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD37 & CD64

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL)

Targets

Target 1

CD37

Gene ID

951

UniProt ID

P11049

Alternative Names

CD37; CD37 molecule; GP52-40; TSPAN26; leukocyte antigen CD37; tspan-26; tetraspanin-26; leukocyte surface antigen CD37; cell differentiation antigen 37

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD37 x Human Anti-CD64 Bispecific Antibody (scFv-CH1/CL) (BSCC-H293). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD37 x Human Anti-CD64 Bispecific Antibody (scFv-CH1/CL) (CAT#: BSCC-H293)

Specifications

Targets

Customer Reviews and Q&As